Faeth Therapeutics (FTH) Common Equity (2020 - 2026)

Faeth Therapeutics (FTH) has reported Common Equity for 7 consecutive years, with $173.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 533.22% year-over-year to $173.0 million; the trailing twelve-month figure through Jun 2026 stood at $173.0 million (up 533.22% YoY), and the FY2025 full-year result was $18.6 million, down 51.57% from the prior year.
• Common Equity grew to $173.0 million in Q2 2026 per FTH's latest filing, from -$137.3 million in the prior quarter.
• Across five years, Common Equity topped out at $173.0 million in Q2 2026 and bottomed at -$137.3 million in Q1 2026.
• Historically, Common Equity has averaged $62.2 million across 5 years, with a median of $61.7 million in 2023.
• The widest YoY moves for Common Equity: up 533.22% in 2026, down 529.19% in 2026.
• Over 5 years, Common Equity stood at $103.4 million in 2022, then tumbled by 37.24% to $64.9 million in 2023, then tumbled by 40.85% to $38.4 million in 2024, then tumbled by 51.57% to $18.6 million in 2025, then jumped by 830.28% to $173.0 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $173.0 million, -$137.3 million, and $18.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.